These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23967166)

  • 1. Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.
    Marazioti A; Kairi CA; Spella M; Giannou AD; Magkouta S; Giopanou I; Papaleonidopoulos V; Kalomenidis I; Snyder LA; Kardamakis D; Stathopoulos GT
    PLoS One; 2013; 8(8):e71207. PubMed ID: 23967166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.
    Stathopoulos GT; Sherrill TP; Karabela SP; Goleniewska K; Kalomenidis I; Roussos C; Fingleton B; Yull FE; Peebles RS; Blackwell TS
    Am J Respir Crit Care Med; 2010 Nov; 182(10):1273-81. PubMed ID: 20595227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-alpha promotes malignant pleural effusion.
    Stathopoulos GT; Kollintza A; Moschos C; Psallidas I; Sherrill TP; Pitsinos EN; Vassiliou S; Karatza M; Papiris SA; Graf D; Orphanidou D; Light RW; Roussos C; Blackwell TS; Kalomenidis I
    Cancer Res; 2007 Oct; 67(20):9825-34. PubMed ID: 17942913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mast cells mediate malignant pleural effusion formation.
    Giannou AD; Marazioti A; Spella M; Kanellakis NI; Apostolopoulou H; Psallidas I; Prijovich ZM; Vreka M; Zazara DE; Lilis I; Papaleonidopoulos V; Kairi CA; Patmanidi AL; Giopanou I; Spiropoulou N; Harokopos V; Aidinis V; Spyratos D; Teliousi S; Papadaki H; Taraviras S; Snyder LA; Eickelberg O; Kardamakis D; Iwakura Y; Feyerabend TB; Rodewald HR; Kalomenidis I; Blackwell TS; Agalioti T; Stathopoulos GT
    J Clin Invest; 2015 Jun; 125(6):2317-34. PubMed ID: 25915587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
    Stathopoulos GT; Psallidas I; Moustaki A; Moschos C; Kollintza A; Karabela S; Porfyridis I; Vassiliou S; Karatza M; Zhou Z; Joo M; Blackwell TS; Roussos C; Graf D; Kalomenidis I
    J Natl Cancer Inst; 2008 Oct; 100(20):1464-76. PubMed ID: 18840818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
    Psallidas I; Karabela SP; Moschos C; Sherrill TP; Kollintza A; Magkouta S; Theodoropoulou P; Roussos C; Blackwell TS; Kalomenidis I; Stathopoulos GT
    Mol Cancer; 2010 Mar; 9():56. PubMed ID: 20219102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant KRAS promotes malignant pleural effusion formation.
    Agalioti T; Giannou AD; Krontira AC; Kanellakis NI; Kati D; Vreka M; Pepe M; Spella M; Lilis I; Zazara DE; Nikolouli E; Spiropoulou N; Papadakis A; Papadia K; Voulgaridis A; Harokopos V; Stamou P; Meiners S; Eickelberg O; Snyder LA; Antimisiaris SG; Kardamakis D; Psallidas I; Marazioti A; Stathopoulos GT
    Nat Commun; 2017 May; 8():15205. PubMed ID: 28508873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies.
    Tsui P; Das A; Whitaker B; Tornetta M; Stowell N; Kesavan P; Kaiser E; Lacy ER; Yan L; Snyder LA; Sweet R
    Hum Antibodies; 2007; 16(3-4):117-25. PubMed ID: 18334747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion.
    Stathopoulos GT; Zhu Z; Everhart MB; Kalomenidis I; Lawson WE; Bilaceroglu S; Peterson TE; Mitchell D; Yull FE; Light RW; Blackwell TS
    Am J Respir Cell Mol Biol; 2006 Feb; 34(2):142-50. PubMed ID: 16210694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion.
    Psallidas I; Stathopoulos GT; Maniatis NA; Magkouta S; Moschos C; Karabela SP; Kollintza A; Simoes DC; Kardara M; Vassiliou S; Papiris SA; Roussos C; Kalomenidis I
    Oncogene; 2013 Jan; 32(4):528-35. PubMed ID: 22370646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion.
    Vazakidou ME; Magkouta S; Moschos C; Kalomenidis I
    Respirology; 2014 Feb; 19(2):290-292. PubMed ID: 23819792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
    Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
    Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The angiopoietin/Tie2 axis mediates malignant pleural effusion formation.
    Moschos C; Psallidas I; Kollintza A; Karabela S; Papapetropoulos A; Papiris S; Light RW; Roussos C; Stathopoulos GT; Kalomenidis I
    Neoplasia; 2009 Mar; 11(3):298-304. PubMed ID: 19242611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of tissue factor by activated Stat3 contributes to malignant pleural effusion generation via enhancing tumor metastasis and vascular permeability in lung adenocarcinoma.
    Yeh HH; Chang WT; Lu KC; Lai WW; Liu HS; Su WC
    PLoS One; 2013; 8(9):e75287. PubMed ID: 24086497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant pleural effusion: tumor-host interactions unleashed.
    Stathopoulos GT; Kalomenidis I
    Am J Respir Crit Care Med; 2012 Sep; 186(6):487-92. PubMed ID: 22652027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
    Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
    Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCL2 blockade augments cancer immunotherapy.
    Fridlender ZG; Buchlis G; Kapoor V; Cheng G; Sun J; Singhal S; Crisanti MC; Wang LC; Heitjan D; Snyder LA; Albelda SM
    Cancer Res; 2010 Jan; 70(1):109-18. PubMed ID: 20028856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid is effective against experimental malignant pleural effusion.
    Stathopoulos GT; Moschos C; Loutrari H; Kollintza A; Psallidas I; Karabela S; Magkouta S; Zhou Z; Papiris SA; Roussos C; Kalomenidis I
    Am J Respir Crit Care Med; 2008 Jul; 178(1):50-9. PubMed ID: 18388351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
    Zhu X; Fujita M; Snyder LA; Okada H
    J Neurooncol; 2011 Aug; 104(1):83-92. PubMed ID: 21116835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-17 inhibits development of malignant pleural effusion via interleukin-9-dependent mechanism.
    Lu Y; Lin H; Zhai K; Wang X; Zhou Q; Shi H
    Sci China Life Sci; 2016 Dec; 59(12):1297-1304. PubMed ID: 27535421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.